Talk Summary: Viscient Biosciences LLC is an early stage biotech startup focused on exploiting the advantages of 3D cell culture disease models for drug discovery across therapeutic areas. We believe that the unique cell cell interactions, context dependent localization and complexity of human primary cell 3D culture will provide a rich supply of potential drug targets and an improved success rate once clinical trials are initiated. Our first focus is on understanding the disease biology of NAFLD and NASH in the 3D context in order to discover and develop novel therapies for this progressive and difficult to treat disease.
Jeffrey N. Miner is a Founder and Chief Scientific Officer for Viscient Biosciences. Prior to Viscient, Dr. Miner held research leadership positions at Ardea Biosciences, a member of the Astrazeneca group, and Ligand Pharmaceuticals. His responsibilities at Ardea covered the Biology program as it relates to discovery, preclinical, translational and clinical development. He was head of molecular and cellular biology at Ligand pharmaceuticals. He is a Faculty Advisor and Molecular Biology Institute Associate at San Diego State University and is a scientific advisory board member for ARTA Bioscience. His Ph.D. graduate work was conducted in virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target expertise includes Nuclear Receptors, Kinases and Transporters. He has published over 60 peer reviewed articles and book chapters and is an inventor on multiple patents.
Dr. Miner will be a speaker at 3DHEALS2018.